Indian pharma wants compulsory license on AZ's Onglyza; Novo pulls out of GLP-1 patch deal;

@FiercePharma: USDA amends rules to allow vets to make custom vaccines in their offices. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Bayer draws up big sales plans for ex-Merck OTC meds. Story | Follow @CarlyHFierce

> A little-known Indian pharma company asked the country's patent office for a compulsory license on AstraZeneca's ($AZN) diabetes med Onglyza, which would force low-cost copycats onto the domestic market. Report

> Novo Nordisk ($NVO) pulled out of a collaboration with Zosano Pharma, which had been working on a patch version of GLP-1 diabetes treatment. Report

> Boehringer Ingelheim's cancer med Giotrif beat Roche's ($RHHBY) Tarceva in a head-to-head trial in previously treated patient with squamous lung cancer. Report

> European biotech companies are turning to U.S. markets to list their shares, finding stateside listings more lucrative. Report

> Japanese drugmaker Astellas was taken to task by U.K. drug-promotion watchdogs for an event promoting the prostate cancer drug Xtandi. Report

Medical Device News

@FierceMedDev: ICYMI: Quest and Quintiles rev up new lab testing JV. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Greek referendum: Next big deadline is payment to ECB (assuming no bank run). Sad & ironic that technocrats still have to make this decision. | Follow @VarunSaxena2

@EmilyWFierce: A Perfect Blood Test For Pancreatic Cancer? Forbes story | Follow @EmilyWFierce

> Report: Despite growth in the device industry, effective concussion treatment remains elusive. More

> Allergan to buy dry eye device startup Oculeve for $125M+. News

Biotech News

@FierceBiotech: Analyst Schoenebaum offers best-case scenario for Axovant's 4-time Alzheimer's loser. More | Follow @FierceBiotech

@JohnCFierce: The dog that didn't bark? Odd that $AXON trolls haven't been on my tail. Where are the die-hard fanatics? Is this mostly an insiders' game? | Follow @JohnCFierce

> 23andMe raises $79M as it ramps up R&D work. Item

> Novo Nordisk backs out of a diabetes deal with Zosano. Story

> Versartis gets out from under the FDA with its growth hormone treatment. Article

Pharma Marketing News

> Hot summer ad wars: Celgene launches Otezla DTC into crowded psoriasis drug market. More

> Sanofi, Regeneron break out the popcorn for cholesterol-fighting, PCSK9-friendly documentary. Story

> Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Article

> Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach. Item

> Hotel workers lobby to stop Big Pharma funding for CME. More

Animal Health News

> Flu season over? Not for dogs. Item

> Patterson offloads medical unit to private equity firm for $715M, boosts focus on animal health. Report

> Report: With Valeant takeover rumors fading, could Zoetis buy IDEXX? More

> USDA amends rules to allow vets to make custom vaccines in their offices. Story

> FDA, Gates Foundation call for improved global access to veterinary drugs. Article

Biotech IT News

> Broad Institute snaps up GemCode Platform as 10X Genomics starts shipping. News

> Novartis steps into wearables with app for Apple Watch, Android Wear. More

> Mousera bags $20M VC round to advance sensor tech in preclinical research. Story

> BioClinica mounts European expansion to push imaging and eClinical. Article

> Congressman pushes to unshackle pharma on social media. Report

And Finally... A contraception campaign in Colorado has driven down the number of teen pregnancies dramatically. Report